---
document_datetime: 2025-12-29 08:38:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/victoza.html
document_name: victoza.html
version: success
processing_time: 0.2721238
conversion_datetime: 2025-12-30 19:58:48.163874
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Victoza

[RSS](/en/individual-human-medicine.xml/65765)

##### Authorised

This medicine is authorised for use in the European Union

liraglutide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Victoza](#news-on)
- [External links](#external-links-519)
- [More information on Victoza](#more-information-on-victoza-1083)
- [More information on Victoza](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Victoza is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes.

Victoza is used:

- on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
- as an 'add-on' to other diabetes medicines.

Victoza contains the active substance liraglutide.

Expand section

Collapse section

## How is Victoza used?

Victoza is a solution for injection available in pre?filled pens (6 mg/ml). Victoza is given by the patient once a day by injection under the skin in the abdomen, thigh or upper arm. It is given independent of meals and preferably at the same time each day.

The starting dose of Victoza is 0.6 mg. After at least one week, the dose is increased to 1.2 mg. In some patients, the dose can be further increased to 1.8 mg one week later to achieve better control of blood glucose.

When Victoza is added to existing treatment containing metformin, thiazolidinedione or a sodium-glucose cotransporter 2 inhibitor (SGLT2i), the doses of these medicines do not have to be changed. When Victoza is added to treatment with a sulphonylurea or insulin, the doctor should consider lowering the dose of the other medicine to reduce the risk of having hypoglycaemia (low blood glucose).

The medicine can only be obtained with a prescription. For more information about using Victoza, see the package leaflet or contact your doctor or pharmacist.

## How does Victoza work?

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively. The active substance in Victoza, liraglutide, is an 'incretin mimetic'. This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food. This helps with the control of blood glucose levels.

## What benefits of Victoza have been shown in studies?

Victoza was effective at controlling blood glucose in six main studies involving 4,289 adults and children with type 2 diabetes. In these studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c) after six months or one year of treatment. HbA1c gives an indication of how well the blood glucose is controlled.

In one 'monotherapy' study in adults, Victoza on its own was compared with glimepiride (a sulphonylurea). Victoza used on its own was more effective at controlling blood glucose than glimepiride. Results from this study show that Victoza at a dose of 1.2 mg reduced HbA1c by 0.8 percentage points, whereas Victoza at a dose of 1.8 mg led to reductions of 1.1 percentage points. This compared with a reduction of 0.5 percentage points with glimepiride.

In two 'dual therapy' adult studies, Victoza plus metformin or Victoza plus glimepiride were compared with metformin or glimepiride taken with a placebo (a dummy treatment). Combinations containing Victoza were more effective at controlling blood glucose than combinations without the medicine. Dual therapies containing Victoza and metformin or glimepiride led to reductions in HbA1c of around 1 percentage point compared with no reduction without Victoza.

In two 'triple therapy' adult studies, Victoza with metformin and either glimepiride or rosiglitazone (a thiazolidinedione) were compared with treatments that included placebo or another anti?diabetes medicine instead of Victoza. The triple therapies containing Victoza led to a reduction of between 1.3 and 1.5 percentage points compared with a reduction equal or less than 0.5 points without Victoza.

In another triple therapy adult study, Victoza was compared with a single dose of a short-acting insulin, insulin aspart, when added to treatment with basal insulin (a long-acting insulin) plus metformin. Adding Victoza to treatment with basal insulin plus metformin reduced HbA1c by 0.7 percentage points, compared with 0.4 points when adding Victoza to insulin aspart.

In a study in 134 adolescents and children from 10 years of age Victoza was found to be more effective than placebo. In this study, HbA1c fell by 0.64 percentage points in patients treated with Victoza while HbA1c increased by 0.42 points in patients treated with placebo.

In addition to the above studies, Victoza in adults was shown to be effective in reducing adverse cardiovascular (heart and blood vessels) effects. The study involved 9,340 patients with type 2 diabetes who already had cardiovascular disease (such as angina, heart attack or stroke). The main measure of effectiveness was the occurrence of one of three major cardiovascular events: stroke, heart attack or death caused by cardiovascular disease. Victoza was compared with placebo and all patients also received standard care. Patients were followed up on average for 3.8 years. Cardiovascular events occurred in 13% (608 out of 4668) of patients taking Victoza compared with 14.9% (694 out of 4672) of patients taking placebo.

## What are the risks associated with Victoza?

The most common side effects with Victoza (seen in more than 1 patient in 10) are nausea and diarrhoea. These side effects usually pass after a few days or weeks of treatment. For the full list of side effects and restrictions with Victoza, see the package leaflet.

## Why is Victoza authorised in the EU?

The European Medicines Agency decided that Victoza's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Victoza?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Victoza have  been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Victoza are continuously monitored. Side effects reported with Victoza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Victoza

Victoza received a marketing authorisation valid throughout the EU on 30 June 2009.

Victoza : EPAR - Medicine overview

English (EN) (140.31 KB - PDF)

**First published:** 08/07/2009

**Last updated:** 29/04/2021

[View](/en/documents/overview/victoza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-353)

български (BG) (165.91 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/bg/documents/overview/victoza-epar-medicine-overview_bg.pdf)

español (ES) (139.69 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/es/documents/overview/victoza-epar-medicine-overview_es.pdf)

čeština (CS) (164.66 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/cs/documents/overview/victoza-epar-medicine-overview_cs.pdf)

dansk (DA) (138.79 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/da/documents/overview/victoza-epar-medicine-overview_da.pdf)

Deutsch (DE) (143.08 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/de/documents/overview/victoza-epar-medicine-overview_de.pdf)

eesti keel (ET) (128.21 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/et/documents/overview/victoza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (163.79 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/el/documents/overview/victoza-epar-medicine-overview_el.pdf)

français (FR) (141.67 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/fr/documents/overview/victoza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.14 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/hr/documents/overview/victoza-epar-medicine-overview_hr.pdf)

italiano (IT) (138.55 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/it/documents/overview/victoza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (179.29 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/lv/documents/overview/victoza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (165.03 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/lt/documents/overview/victoza-epar-medicine-overview_lt.pdf)

magyar (HU) (161.25 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/hu/documents/overview/victoza-epar-medicine-overview_hu.pdf)

Malti (MT) (179.62 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/mt/documents/overview/victoza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (139.3 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/nl/documents/overview/victoza-epar-medicine-overview_nl.pdf)

polski (PL) (166.03 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/pl/documents/overview/victoza-epar-medicine-overview_pl.pdf)

português (PT) (140.78 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/pt/documents/overview/victoza-epar-medicine-overview_pt.pdf)

română (RO) (161.15 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/ro/documents/overview/victoza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.97 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/sk/documents/overview/victoza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.14 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/sl/documents/overview/victoza-epar-medicine-overview_sl.pdf)

Suomi (FI) (137.29 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/fi/documents/overview/victoza-epar-medicine-overview_fi.pdf)

svenska (SV) (138.29 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

29/04/2021

[View](/sv/documents/overview/victoza-epar-medicine-overview_sv.pdf)

Victoza : EPAR - Risk-management-plan summary

English (EN) (79.65 KB - PDF)

**First published:** 15/10/2019

[View](/en/documents/rmp-summary/victoza-epar-risk-management-plan-summary_en.pdf)

## Product information

Victoza : EPAR - Product Information

English (EN) (480.11 KB - PDF)

**First published:** 08/07/2009

**Last updated:** 20/02/2025

[View](/en/documents/product-information/victoza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-401)

български (BG) (689.49 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/bg/documents/product-information/victoza-epar-product-information_bg.pdf)

español (ES) (514.88 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/es/documents/product-information/victoza-epar-product-information_es.pdf)

čeština (CS) (668.35 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/cs/documents/product-information/victoza-epar-product-information_cs.pdf)

dansk (DA) (517.11 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/da/documents/product-information/victoza-epar-product-information_da.pdf)

Deutsch (DE) (535.52 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/de/documents/product-information/victoza-epar-product-information_de.pdf)

eesti keel (ET) (500.34 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/et/documents/product-information/victoza-epar-product-information_et.pdf)

ελληνικά (EL) (638.43 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/el/documents/product-information/victoza-epar-product-information_el.pdf)

français (FR) (536.94 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/fr/documents/product-information/victoza-epar-product-information_fr.pdf)

hrvatski (HR) (632.94 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/hr/documents/product-information/victoza-epar-product-information_hr.pdf)

íslenska (IS) (515.11 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/is/documents/product-information/victoza-epar-product-information_is.pdf)

italiano (IT) (525.09 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/it/documents/product-information/victoza-epar-product-information_it.pdf)

latviešu valoda (LV) (639.11 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/lv/documents/product-information/victoza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (607.21 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/lt/documents/product-information/victoza-epar-product-information_lt.pdf)

magyar (HU) (620.91 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/hu/documents/product-information/victoza-epar-product-information_hu.pdf)

Malti (MT) (684.37 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/mt/documents/product-information/victoza-epar-product-information_mt.pdf)

Nederlands (NL) (470.35 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/nl/documents/product-information/victoza-epar-product-information_nl.pdf)

norsk (NO) (490.07 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/no/documents/product-information/victoza-epar-product-information_no.pdf)

polski (PL) (633.5 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/pl/documents/product-information/victoza-epar-product-information_pl.pdf)

português (PT) (494.53 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/pt/documents/product-information/victoza-epar-product-information_pt.pdf)

română (RO) (665.18 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/ro/documents/product-information/victoza-epar-product-information_ro.pdf)

slovenčina (SK) (615 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/sk/documents/product-information/victoza-epar-product-information_sk.pdf)

slovenščina (SL) (621.62 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/sl/documents/product-information/victoza-epar-product-information_sl.pdf)

Suomi (FI) (488.58 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/fi/documents/product-information/victoza-epar-product-information_fi.pdf)

svenska (SV) (514.58 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

20/02/2025

[View](/sv/documents/product-information/victoza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00001892/202312 19/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Victoza : EPAR - All Authorised presentations

English (EN) (12.24 KB - PDF)

**First published:** 08/07/2009

**Last updated:** 08/07/2009

[View](/en/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-419)

български (BG) (81.39 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/bg/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.79 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/es/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (82.74 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/cs/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.6 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/da/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.81 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/de/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.82 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/et/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.88 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/el/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_el.pdf)

français (FR) (12.73 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/fr/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (12.58 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/it/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (84.12 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/lv/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.44 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/lt/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (81.22 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/hu/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.16 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/mt/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.13 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/nl/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_nl.pdf)

polski (PL) (84.95 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/pl/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.78 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/pt/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.48 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/ro/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (79.77 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/sk/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (43.74 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/sl/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.81 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/fi/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.05 KB - PDF)

**First published:**

08/07/2009

**Last updated:**

08/07/2009

[View](/sv/documents/all-authorised-presentations/victoza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Victoza Active substance liraglutide International non-proprietary name (INN) or common name liraglutide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ02

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.

## Authorisation details

EMA product number EMEA/H/C/001026 Marketing authorisation holder

Novo Nordisk A/S

Novo Allé

Opinion adopted 23/04/2009 Marketing authorisation issued 30/06/2009 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Victoza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (258.29 KB - PDF)

**First published:** 22/02/2010

**Last updated:** 20/02/2025

[View](/en/documents/procedural-steps-after/victoza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Victoza-H-C-1026-P46-038 : EPAR - Assessment report

Adopted

Reference Number: EMA/93156/2021

English (EN) (594.72 KB - PDF)

**First published:** 29/04/2021

[View](/en/documents/variation-report/victoza-h-c-1026-p46-038-epar-assessment-report_en.pdf)

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/85138/2021

English (EN) (160.54 KB - PDF)

**First published:** 11/02/2021

[View](/en/documents/scientific-conclusion/victoza-h-c-1026-psusa-00001892-201912-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Victoza-H-C-PSUSA-00001892- 201812: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/429077/2019

English (EN) (67.69 KB - PDF)

**First published:** 07/11/2019

[View](/en/documents/scientific-conclusion/victoza-h-c-psusa-00001892-201812-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Victoza-H-C-1026-II-0049: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/447330/2019

English (EN) (1.07 MB - PDF)

**First published:** 15/10/2019

[View](/en/documents/variation-report/victoza-h-c-1026-ii-0049-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Victoza (II-49)

Adopted

Reference Number: EMA/CHMP/339781/2019

English (EN) (71.97 KB - PDF)

**First published:** 28/06/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza-ii-49_en.pdf)

Victoza-H-C-1026-II-0042 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/479764/2017

English (EN) (2.08 MB - PDF)

**First published:** 14/09/2017

**Last updated:** 14/09/2017

[View](/en/documents/variation-report/victoza-h-c-1026-ii-0042-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Victoza (II-42)

Reference Number: EMA/CHMP/378657/2017

English (EN) (73.17 KB - PDF)

**First published:** 23/06/2017

**Last updated:** 23/06/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza-ii-42_en.pdf)

Victoza-H-C-1026-PSUSA-00001892- 201512: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (68.62 KB - PDF)

**First published:** 29/09/2016

**Last updated:** 29/09/2016

[View](/en/documents/scientific-conclusion/victoza-h-c-1026-psusa-00001892-201512-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Victoza : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/351673/2016

English (EN) (664.62 KB - PDF)

**First published:** 12/07/2016

**Last updated:** 12/07/2016

[View](/en/documents/variation-report/victoza-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Victoza

Adopted

Reference Number: EMA/CHMP/270952/2016

English (EN) (68.12 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 29/04/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza_en.pdf)

Victoza-H-C-1026-PSUV-0029 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/133394/2015

English (EN) (65.07 KB - PDF)

**First published:** 06/05/2015

**Last updated:** 06/05/2015

[View](/en/documents/scientific-conclusion/victoza-h-c-1026-psuv-0029-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Victoza-H-C-1026-II-0023: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/805158/2013

English (EN) (453.82 KB - PDF)

**First published:** 26/06/2014

**Last updated:** 26/06/2014

[View](/en/documents/scientific-discussion-variation/victoza-h-c-1026-ii-0023-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Victoza

Adopted

Reference Number: EMA/CHMP/164151/2014

English (EN) (67.11 KB - PDF)

**First published:** 21/03/2014

**Last updated:** 21/03/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-victoza_en.pdf-0)

Victoza-H-C-1026-P46-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/149715/2013

English (EN) (777.88 KB - PDF)

**First published:** 25/03/2013

**Last updated:** 25/03/2013

[View](/en/documents/variation-report/victoza-h-c-1026-p46-0029-epar-assessment-report_en.pdf)

Victoza-H-C-1026-II-0005-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/857940/2011

English (EN) (1.64 MB - PDF)

**First published:** 12/12/2011

**Last updated:** 12/12/2011

[View](/en/documents/variation-report/victoza-h-c-1026-ii-0005-g-epar-assessment-report-variation_en.pdf)

Questions and answers on the outcome of extension of indication application for Victoza (liraglutide)

Adopted

Reference Number: EMA/770558/2011

English (EN) (53.51 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 23/09/2011

[View](/en/documents/smop/questions-and-answers-outcome-extension-indication-application-victoza-liraglutide_en.pdf)

## Initial marketing authorisation documents

Victoza : EPAR - Public assessment report

English (EN) (1.11 MB - PDF)

**First published:** 09/07/2009

**Last updated:** 09/07/2009

[View](/en/documents/assessment-report/victoza-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for  Victoza

Reference Number: EMEA/CHMP/141689/2009

English (EN) (34.06 KB - PDF)

**First published:** 23/04/2009

**Last updated:** 23/04/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-victoza_en.pdf)

#### News on Victoza

[Warning about sharp rise in illegal medicines sold in the EU](/en/news/warning-about-sharp-rise-illegal-medicines-sold-eu) 03/09/2025

[EU actions to tackle shortages of GLP-1 receptor agonists](/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists) 26/06/2024

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019) 28/06/2019

[New treatment for children with type 2 diabetes](/en/news/new-treatment-children-type-2-diabetes) 28/06/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-june-2017) 23/06/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-april-2016) 29/04/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 March 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-march-2014) 21/03/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-september-2011) 23/09/2011

#### External links

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC001026II0038) (variation II/0038)

#### More information on Victoza

Questions and answers on the outcome of extension of indication application for Victoza (liraglutide)

Adopted

Reference Number: EMA/770558/2011

English (EN) (53.51 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 23/09/2011

[View](/en/documents/smop/questions-and-answers-outcome-extension-indication-application-victoza-liraglutide_en.pdf)

#### More information on Victoza

- [EMEA-000128-PIP01-07-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000128-pip01-07-m08)
- [Victoza - supply shortage](/en/medicines/human/shortages/victoza)
- [Ozempic / Victoza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic-victoza)
- [Ozempic / Victoza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/ozempic-victoza-0)
- [DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000223)
- [Incretin-based therapies and Pancreatic Cancer risk in Medicare enrollees - new user protocol - post-authorisation study](https://catalogues.ema.europa.eu/study/8912)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/02/2025

## Share this page

[Back to top](#main-content)